

SynAct Pharma to join J.P. Morgan Healthcare Conference in San Francisco

SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, announced that CEO Jeppe Øvlesen will participate at the 44th J.P. Morgan Healthcare Conference on January 12-15, 2026, in San Francisco, CA, USA.

"The J.P. Morgan Healthcare Conference is one of the biggest platforms of the year for engaging with potential partners, and we are excited to discuss with potential partners and investors about our progress with resomelagon for rheumatoid arthritis and for host directed treatment in viral infections," said Jeppe Øvlesen, Chief Executive Officer of SynAct Pharma.

For further information, please contact:

Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: <https://synactpharma.com/>.

Attachments

[SynAct Pharma to join J.P. Morgan Healthcare Conference in San Francisco](#)